Dingdang Health Technology Group (Dingdang Health) disclosed a material reduction in its share capital following a series of repurchase activities executed on 16 July 2026.

On 16 July, the company cancelled 14.34 million ordinary shares that had been repurchased between 19 May and 8 July 2026 and simultaneously bought back an additional 0.20 million shares on-market to be held as treasury stock. The latest on-market repurchase was executed at prices ranging from HK$0.90 to HK$0.92, resulting in a volume-weighted average price of HK$0.912 and an aggregate consideration of HK$0.18 million.

These actions reduced Dingdang Health’s issued share capital (excluding treasury shares) from 1.25 billion to 1.24 billion, a decline of approximately 14.54 million shares or 1.16%. Treasury stock increased to 0.88 million shares, bringing total issued shares—including treasury—to 1.24 billion as of 16 July 2026.

The repurchases form part of the mandate approved by shareholders on 23 June 2026, which authorises the company to repurchase up to 124.32 million shares. To date, 3.74 million shares—equivalent to 0.30% of the company’s issued share base at the time of the mandate—have been repurchased under this authorisation.

In accordance with Hong Kong Stock Exchange rules, Dingdang Health is subject to a moratorium on issuing new shares or disposing of treasury shares until 15 August 2026.